Lakeshore Capital Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$974K Buy
1,059
+7
+0.7% +$7.1K 0.8% 42
2025
Q4
$1.13M Buy
1,052
+2
+0.2% +$1.91K 0.9% 33
2025
Q3
$801K Buy
1,050
+20
+2% +$14.9K 0.65% 45
2025
Q2
$803K Buy
1,030
+5
+0.5% +$3.88K 0.71% 43
2025
Q1
$847K Buy
1,025
+15
+1% +$12.5K 0.82% 40
2024
Q4
$779K Buy
+1,010
New +$836K 1.18% 30

Other funds holding LLY

Lakeshore Capital Group's LLY Position: Q1 2026 in Review

Lakeshore Capital Group increased its Eli Lilly (LLY) stake by 0.67% in Q1 2026, buying an estimated $7.1K and bringing the position to 1,059 shares worth $974K. The position accounts for 0.8% of the portfolio, ranked #42.

Lakeshore Capital Group first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.13M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Lakeshore Capital Group held 1,059 shares of Eli Lilly worth $974K as of Q1 2026.
  • Lakeshore Capital Group bought 7 Eli Lilly shares in Q1 2026, an estimated $7.1K.
  • Eli Lilly made up 0.8% of Lakeshore Capital Group's portfolio in Q1 2026, its #42 holding.
  • Lakeshore Capital Group first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • Lakeshore Capital Group's Eli Lilly position peaked at $1.13M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Lakeshore Capital Group's 13F filing for Q1 2026, filed 22 Apr 2026.